Several studies reported that HER2+ breast cancer has more TAM infiltration (CD68-positive 10, 16; CD163-positive 9, 14, 16), while the majority of the included studies failed to reveal a significant relationship between HER2 expression and TAMs in breast cancer. This evidence concerns the gene CD163 and breast cancer.